



OPEN

SUBJECT AREAS:  
TRANSLATIONAL  
RESEARCHIMAGING TECHNIQUES AND  
AGENTSReceived  
24 September 2014Accepted  
15 January 2015Published  
12 February 2015Correspondence and  
requests for materials  
should be addressed to  
S.W. (sonia@  
waiczies.de)\* These authors  
contributed equally to  
this work.

# Anchoring Dipalmitoyl Phosphoethanolamine to Nanoparticles Boosts Cellular Uptake and Fluorine-19 Magnetic Resonance Signal

Sonia Waiczies<sup>1\*</sup>, Stefano Lepore<sup>1\*</sup>, Karl Sydow<sup>2\*</sup>, Susanne Drechsler<sup>1</sup>, Min-Chi Ku<sup>1</sup>, Conrad Martin<sup>1</sup>, Dorothea Lorenz<sup>2</sup>, Irene Schütz<sup>2</sup>, Henning M. Reimann<sup>1</sup>, Bettina Purfürst<sup>4</sup>, Matthias A. Dieringer<sup>1,5</sup>, Helmar Waiczies<sup>3</sup>, Margitta Dathe<sup>2</sup>, Andreas Pohlmann<sup>1</sup> & Thoralf Niendorf<sup>1</sup>

<sup>1</sup>Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine, Berlin, Germany, <sup>2</sup>Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany, <sup>3</sup>MRI TOOLS GmbH, Berlin, Germany, <sup>4</sup>Electron Microscopy Core Facility, Max Delbrück Center for Molecular Medicine, Berlin, Germany, <sup>5</sup>Experimental and Clinical Research Center, Berlin, Germany.

Magnetic resonance (MR) methods to detect and quantify fluorine (<sup>19</sup>F) nuclei provide the opportunity to study the fate of cellular transplants *in vivo*. Cells are typically labeled with <sup>19</sup>F nanoparticles, introduced into living organisms and tracked by <sup>19</sup>F MR methods. Background-free imaging and quantification of cell numbers are amongst the strengths of <sup>19</sup>F MR-based cell tracking but challenges pertaining to signal sensitivity and cell detection exist. In this study we aimed to overcome these limitations by manipulating the aminophospholipid composition of <sup>19</sup>F nanoparticles in order to promote their uptake by dendritic cells (DCs). As critical components of biological membranes, phosphatidylethanolamines (PE) were studied. Both microscopy and MR spectroscopy methods revealed a striking (at least one order of magnitude) increase in cytoplasmic uptake of <sup>19</sup>F nanoparticles in DCs following enrichment with 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE). The impact of enriching <sup>19</sup>F nanoparticles with PE on DC migration was also investigated. By manipulating the nanoparticle composition and as a result the cellular uptake we provide here one way of boosting <sup>19</sup>F signal per cell in order to overcome some of the limitations related to <sup>19</sup>F MR signal sensitivity. The boost in signal is ultimately necessary to detect and track cells *in vivo*.

**T**racking immune cells *in vivo* is a prerequisite for understanding the development of pathologies associated with disorders of the immune system<sup>1</sup>. Dendritic cells (DCs) are immune cells that play key roles in the development of immunity and immunopathology. Of note, an understanding of the distribution and fate of cells such as DCs following their therapeutic application *in vivo* such as in cancers is crucial to assess treatment efficacy<sup>2</sup>. The lack of *a priori* knowledge of the kinetics and dynamics of these cells during physiological and pathological settings makes their localization a challenging task. It is therefore a top priority to develop methods for the non-invasive spatiotemporal tracking of immune cells *in vivo* that can be easily transferred to the clinical scenario<sup>3–6</sup>.

Magnetic resonance imaging (MRI) offers an ideal solution for tracking cells *in vivo* due to its non-invasiveness and clinical translation as well as the opportunity of repetitive measurements and longitudinal studies. Major challenges in differentiating cells from the recipient tissue and signal sensitivity constraints nevertheless exist. For instance, iron oxide nanoparticles that reduce  $T_2^*$  relaxation<sup>7</sup> in MR have been used to label cells, however present a challenge whereby the contrast created by the labeled cells is not easily distinguishable from other intrinsic tissue contrasts<sup>8</sup>. This limitation of cellular MRI is surmounted by fluorine (<sup>19</sup>F) MR techniques<sup>9</sup>. Carbon-bound fluorine is absent in living organisms. This guarantees background-free MR signals for externally-applied <sup>19</sup>F compounds. Therefore <sup>19</sup>F MR techniques are advantageous for localizing <sup>19</sup>F-containing exogenous agents *in vivo* since they permit complete signal selectivity and specificity<sup>9–11</sup>. Importantly, the <sup>19</sup>F MR signal can also be equated to measurable cell numbers within defined regions<sup>6,12</sup>. For *in vivo* tracking, cells are typically labeled with nanoparticles enriched with perfluorocompounds (PFCs) prior to their introduction into living organisms<sup>3–6</sup>. These compounds possess unique properties (inertness, biocompatibility and hydrophobicity) which stem from




the C-F bonds within the molecular structure<sup>13</sup>. Hydrophobicity becomes more significant with increasing number of <sup>19</sup>F atoms and a critical factor for increasing the ability of these compounds to cross biological membranes<sup>14,15</sup>. Making use of these properties, <sup>19</sup>F-rich nanoparticles are prepared via various techniques – commonly by emulsifying PFCs with phospholipids or surfactants – in order to label and track immune cells *in vivo* with the aid of combined <sup>19</sup>F and anatomical/proton (<sup>1</sup>H) MR imaging as well as <sup>19</sup>F spectroscopy techniques<sup>3–6</sup>. Notwithstanding the benefits specified above, some limitations and challenges exist for <sup>19</sup>F-based MR techniques, especially those pertaining to detection limit and signal sensitivity. These limitations come at a cost in increased signal averaging and thus acquisition times to compensate for low signal-to-noise ratio (SNR). There is a need to optimize cellular <sup>19</sup>F MR methods especially since clinical trials with DC vaccines have thus far provided a proof-of-principle as cancer therapy<sup>16</sup> and the applicability of <sup>19</sup>F MR techniques for DC vaccines are being explored in colorectal cancer patients<sup>17</sup>.

In the present study we explored the possibility of altering the composition of <sup>19</sup>F nanoparticles in order to maximize their uptake by DCs and therefore to promote the <sup>19</sup>F signal per cell. To meet this goal, we investigated the incorporation of phosphatidylethanolamines (PEs) into the <sup>19</sup>F nanoparticle shell. PEs are aminophospholipids that constitute an integral part of biological membranes<sup>18,19</sup>. These aminophospholipids are cone-shaped, they do not form bilayers but inverted hexagonal phases, are believed to exert a lateral pressure that regulates membrane curvature and, are thought to stabilize membrane proteins in their optimum conformations<sup>20</sup>. PE analogs have been used successfully in non-viral transfection systems<sup>21,22</sup> as well as in nanotube carriers for drug delivery<sup>23</sup>. For all these reasons we studied the influence of PE enrichment on the uptake of <sup>19</sup>F nanoparticle by DCs. Using both electron microscopy and <sup>19</sup>F MR spectroscopy we observed a dramatic increase in uptake of <sup>19</sup>F nanoparticles enriched with 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) by DCs. As a result, the <sup>19</sup>F signal/cell was increased by at least one order of magnitude and the cell detection limit considerably reduced. With this advantage at hand we could reduce the PFCE concentration per nanoparticle to avoid impairment in cell function, particularly cell migration. Our findings further offset the constraints of <sup>19</sup>F MR and bring us a step closer to the crucial goal of ultimate signal sensitivity and minimal cell detection limit.

## Results

**Dipalmitoyl-Phosphoethanolamine promotes nanoparticle uptake by DCs.** Considering the power of PE analogs to promote cellular uptake in transfection and drug delivery systems<sup>21–23</sup>, we first set off to enrich <sup>19</sup>F-rich (PFCE) nanoparticles (NP) used in our previous studies<sup>5,6,12</sup> with different phospholipids of the phosphoethanolamine (PE) family (Figure 1A). The basic nanoparticles were prepared using Pluronic F-68 block copolymer. To enrich the <sup>19</sup>F nanoparticles with PE we chose two analogs differing in their two long fatty acid hydrocarbon chains; one PE contained one unsaturated bond (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, POPE) and the other PE consisted of only saturated bonds (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, DPPE). Also consisting solely of saturated bonds was the third candidate we chose: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), bound to polyethylene glycol-2000 (DSPE-PEG2000). PEG is widely employed as polymeric steric stabilizer and is anchored to stealth liposomal surfaces via cross-linked DSPE lipid<sup>24,25</sup>. PEG2000 was chosen since blocks of higher molecular weight in similarly-sized nanoparticles have been shown to reduce nanoparticle uptake in macrophages (uptake: PEG2000 > PEG5000 > PEG10000)<sup>26</sup>. We used DPPE and POPE to enrich Pluronic-based PFCE-containing nanoemulsions and prepared liposomal PFCE nanoparticles using DSPE-PEG2000. For all nanoparticle preparations, the molar fraction of the constituents and the physical characteristics (size, polydispersity, surface charge) are shown in Table 1.

To determine differences in uptake between the different nanoparticle groups we performed <sup>19</sup>F magnetic resonance spectroscopy (MRS) of the fixed DCs following labeling to determine the amount of <sup>19</sup>F compound (PFCE) per  $10^6$  cells. Pluronic-nanoparticles enriched with PE polymers appeared to be taken up more efficiently by DCs than basic Pluronic nanoparticles and DSPE-PEG2000 liposomes as determined by the increase in cellular <sup>19</sup>F signal. POPE enrichment already resulted in an increased <sup>19</sup>F signal (POPE 1x: 138 nmol per  $10^6$  cells and POPE 10x: 179 nmol per  $10^6$  cells) compared to the basic nanoparticle formulations (74 nmol per  $10^6$  cells) and DSPE-PEG2000 liposomes (69 nmol per  $10^6$  cells). When we employed DPPE to enrich the nanoparticle shell, we observed an even stronger enhancement of <sup>19</sup>F signal (771 nmol per  $10^6$  cells) (Figure 1B). This equates to an increase in <sup>19</sup>F spins from  $0.89 \times 10^{12}$  <sup>19</sup>F spins (in basic formulations) to  $0.93 \times 10^{13}$  <sup>19</sup>F spins (in DPPE-enriched nanoparticles) per dendritic cell unit.



**Figure 1 | Selection of phosphoethanolamines for enrichment of PFCE nanoparticles.** (a) Chemical structures of DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) used for the <sup>19</sup>F nanoemulsion and DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000]) used for the liposomal nanoparticles. (b) DCs were labeled with different <sup>19</sup>F nanoparticle preparations (DSPE-PEG2000, Pluronic-POPE and Pluronic-DPPE) using a PFCE concentration of 20  $\mu$ mol per  $10^7$ , fixed in 2% PFA and transferred ( $10^6$ ) to NMR tubes. After positioning in a <sup>19</sup>F-tuned loop coil (see Methods), <sup>19</sup>F signal was acquired using a 90° block excitation pulse with 10 kHz bandwidth and the PFCE amount per  $10^6$  calculated using a 500 mM PFCE standard.




Table 1 | Composition and characteristics of nanoparticles (NP) used

Nanoparticle	Molar fraction of constituents			Physical characteristics		
	Pluronic	PE Lipid	PFCE	Particle size	Polydispersity	Zeta Potential
	X	X	X	[nm] ( $\pm$ S.D.)	Index ( $\pm$ S.D.)	[mV] ( $\pm$ S.D.)
Pluronic-Basic—PFCE NP	0.01419	—	0.98581	186 (15)	0.06 (0.02)	-4.81 (1.52)
Pluronic-(DPPE)—PFCE NP	0.00582	0.00001	0.99417	246 (16)	0.30 (0.02)	-18.55 (1.61)
Pluronic-(POPE 1x)—PFCE NP	0.00580	0.00001	0.99418	200 (6)	0.03 (0.01)	-12.13 (0.31)
Pluronic-(POPE 10x)—PFCE NP	0.00580	0.00011	0.99408	200 (1)	0.12 (0.08)	-7.37 (0.53)
(DSPE-PEG2000)—PFCE NP	—	0.00006	0.99994	216 (19)	0.20 (0.01)	-28.43 (1.33)

Dynamic light scattering was used to measure Z-average diameter (mean diameter based on intensity of scattered light and sensitive to presence of large particles), peak diameter, peak width and polydispersity index (PDI). PFCE = perfluoro-15-crown-5-ether; X = mole fraction; PE = phosphoethanolamine; DPPE = 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; POPE = 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; DSPE-PEG2000 = 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000].

**Intracellular appearance of Dipalmitoyl-Phosphoethanolamine-enriched nanoparticles.** Despite the dramatic differences in  $^{19}\text{F}$  signal within DCs between the different nanoparticles, we did not observe any conspicuous differences in the shape of the nanoparticles employed as investigated by Cryo-TEM (Figure 2A). We next went on to investigate whether the striking increase in  $^{19}\text{F}$  signal in the DPPE-enriched nanoparticles was the result of increased nanoparticle uptake. In ultrathin sections of DCs derived from the same culture conditions, we observed intense differences in cytoplasmic

uptake between the nanoparticle formulations (Figure 2B, *EM images in upper two panels and lower left panel*). We commonly observed the nanoparticles as white globules within the cell cytoplasm but similar to our previous observations<sup>5</sup> the nanoparticles also often appeared compartmentalized as clusters in a lipid membrane capsule within an amorphous grey compartment. We also observed increased DC uptake of nanoparticles enriched with DPPE linked to the tracer dye Rhodamine as shown from the Rhodamine fluorescence imaged by laser scanning microscopy



**Figure 2 | Appearance of phosphoethanolamine-enriched PFCE nanoparticles.** (a) Cryogenic transmission electron microscopy (TEM) images of DSPE-PEG2000, Pluronic-basic, Pluronic-DPPE and Pluronic-DPPE-Rhodamine nanoparticles encapsulating PFCE fluorine compound (size-bar for TEM images: 50 nm). (b) Upper two panels and lower left panel show ultrathin sections of DCs labeled with DSPE-PEG2000, basic and DPPE-enriched PFCE nanoparticles (size-bar for EM images: 2  $\mu\text{m}$ ). Lower right panel shows a laser scanning microscopy image of DCs labeled with DPPE-Rhodamine-enriched  $^{19}\text{F}$  nanoparticles (size-bar for LSM image: 10  $\mu\text{m}$ ). (c) DCs were labeled with different nanoparticle preparations (DSPE-PEG2000 NP, basic NP, DPPE-NP and DPPE-Rhodamine-NP) using a PFCE concentration of 10  $\mu\text{mol}$  per  $10^7$ , fixed in 2% PFA and transferred ( $10^6$ ) to NMR tubes.  $^{19}\text{F}$  signal was acquired using a 90° block excitation pulse and the PFCE amount per  $10^6$  calculated using a 500 mM PFCE standard.




(Figure 2B, *LSM image in lower right panel*); these nanoparticles were also loaded into DCs similarly to the non-Rhodamine linked DPPE-enriched  $^{19}\text{F}$  nanoparticles.

As a next step, the same groups of cells labeled with basic (-), DPPE or DPPE-Rhodamine  $^{19}\text{F}$  nanoparticles as well as DSPE-PEG2000 liposomes were investigated by  $^{19}\text{F}$  MRS (Figure 2C). Similarly to the results in Figure 1B, we observed a significant increase in  $^{19}\text{F}$  signal per cell when DCs were labeled with nanoparticles enriched with DPPE (361 nmol per  $10^6$  cells  $\equiv 0.44 \times 10^{13}$   $^{19}\text{F}$  spins per cell) compared to the basic formulation (25 nmol per  $10^6$  cells  $\equiv 0.3 \times 10^{12}$   $^{19}\text{F}$  spins per cell) and DSPE-PEG2000 liposomes (35 nmol per  $10^6$  cells  $\equiv 0.42 \times 10^{12}$   $^{19}\text{F}$  spins per cell) (Figure 2C). The  $^{19}\text{F}$  signal per cell in DCs labeled with DPPE-Rhodamine nanoparticles was slightly lower (264 nmol per  $10^6$  cells  $\equiv 0.32 \times 10^{13}$   $^{19}\text{F}$  spins per cell) than those from DCs labeled with nanoparticles enriched with DPPE containing no Rhodamine (Figure 2C).


**Titrating the  $^{19}\text{F}$  label in DPPE-enriched nanoparticles.** In the next experiments we performed dose titration curves for the  $^{19}\text{F}$  label (perfluoro-15-crown-5-ether, PFCE) in cells loaded with DPPE or basic  $^{19}\text{F}$  nanoparticles. With these experiments we wanted to determine the lowest concentration of PFCE feasible for detecting a sufficient  $^{19}\text{F}$  signal in MRS (Figure 3). Using the Pluronic-based nanoparticles we had previously employed up to 40  $\mu\text{mol}$  PFCE per  $10^7$  DCs in culture<sup>5</sup>. Taking into account the dramatic increase in  $^{19}\text{F}$  signal achieved following enrichment with DPPE we titrated the PFCE amount from 40  $\mu\text{mol}$  to 2  $\mu\text{mol}$  PFCE per  $10^7$  DCs. In line with the previous results (Figure 1–2), 5  $\mu\text{mol}$  PFCE label within DPPE  $^{19}\text{F}$  nanoparticles gave a larger  $^{19}\text{F}$  signal than 40  $\mu\text{mol}$  PFCE label within basic  $^{19}\text{F}$  nanoparticles when used to label  $10^7$  DCs (Figure 3A, 3B). This observation can be made already from the spectral representations of the  $^{19}\text{F}$  signal (Figure 3A) and upon quantification of the  $^{19}\text{F}$  signal from the maximum signal intensity of the FID (Figure 3B). By extrapolating the linear fit ( $[\text{PFCE}]_{\text{label}} / [\text{PFCE}]_{\text{intracellular}}$ ) for the basic  $^{19}\text{F}$  nanoparticles, we estimate a requirement of 70  $\mu\text{mol}$  for the basic  $^{19}\text{F}$  nanoparticles to reach the equivalent  $^{19}\text{F}$  signal of DCs labeled with 5  $\mu\text{mol}$  DPPE-enriched nanoparticles ( $\Delta$  PFCE concentration  $\sim 65 \mu\text{mol}$ ) (Figure 3B).

**Higher concentrations of  $^{19}\text{F}$  label hinder DC migration.** Ultimately, the  $^{19}\text{F}$ -labeled DCs will be applied in living organisms. Therefore it was necessary to determine the influence of increasing PFCE labeling on DC migration for both DPPE-enriched as well as basic  $^{19}\text{F}$  nanoparticles. For this, we employed an agarose assay to determine the chemotaxis of DCs towards a chemokine gradient following maturation with bacterial lipopolysaccharide (LPS). In the initial experiments comparing  $^{19}\text{F}$  signal between basic and DPPE nanoparticles we employed 10–20  $\mu\text{mol}$  of PFCE to label  $10^7$  cells (Figure 1–2). When we investigated the influence of 10  $\mu\text{mol}$  PFCE label on DC migration, we observed differences in the number of DCs moving towards chemokine between unlabeled cells treated for 18 h with LPS and cells labeled with  $^{19}\text{F}$  nanoparticles (Figure 4A). For DCs labeled with DPPE  $^{19}\text{F}$  nanoparticles, quantities of PFCE higher than 10  $\mu\text{mol}$  per  $10^7$  cells reduced the migration of DCs towards chemokine by more than 50% (Figure 4B). For lower doses of PFCE – specifically 5  $\mu\text{mol}$  per  $10^7$  cells – the reduction in migration was less extensive and the difference between DPPE and basic  $^{19}\text{F}$  nanoparticles less substantial; the inhibition in migration for DPPE-NP labeled cells was 35% ( $n = 1270$ ) and the inhibition in migration for basic-NP labeled DCs was 22% ( $n = 1555$ ) in comparison to unlabeled DCs ( $n = 1985$ ) (Figure 4B). This finding and considering our previous observation that 5  $\mu\text{mol}$  PFCE in DPPE nanoparticles generate an equivalent  $^{19}\text{F}$  signal by at least one order more PFCE in basic nanoparticles (Figure 3B), led us to employ 5  $\mu\text{mol}$  PFCE for all the following experiments.

**Lower number of cells detected following labeling with DPPE-enriched nanoparticles.** Using 5  $\mu\text{mol}$  PFCE for both DPPE and basic  $^{19}\text{F}$  nanoparticles we next measured the intracellular  $^{19}\text{F}$  signal in increasing numbers of DCs to determine the cell detection limit. We measured the  $^{19}\text{F}$  signal in each fixed cell sample by performing global spectroscopy of the NMR tube containing the cell pellet (see Methods). By using a  $^{19}\text{F}$  standard (500 mM PFCE) we quantified the amount of PFCE within each sample. Both spectral representation of the  $^{19}\text{F}$  signal (Figure 5A) as well as PFCE quantification (Figure 5B) for both DPPE-enriched and basic  $^{19}\text{F}$  nanoparticles demonstrated that  $^{19}\text{F}$  signal amplitude correlates with the number of labeled cells.




**Figure 3 | Dose titration of the  $^{19}\text{F}$  label for  $^{19}\text{F}$  NMR signal.** (a) Spectral representation of  $^{19}\text{F}$  signal acquired from basic and DPPE-enriched label within DCs using different doses of the  $^{19}\text{F}$  label PFCE. DCs were labeled with nanoparticle preparations using PFCE concentrations between 2  $\mu\text{mol}$  and 40  $\mu\text{mol}$  per  $10^7$ , fixed in 2% PFA and transferred ( $10^6$ ) to NMR tubes.  $^{19}\text{F}$  signal was acquired using a 90° block excitation pulse and spectral representation using a FFT of the acquired FID. (b) The  $^{19}\text{F}$  signal was quantified from the intercept of the FID fit and the PFCE amount per  $10^6$  was calculated using a 500 mM PFCE standard.




**Figure 4 | Dose titration of the  $^{19}\text{F}$  label for chemotaxis assay.** (a) DCs ( $10^5$ ) labeled with different nanoparticle preparations ( $10 \mu\text{mol}$  PFCE) were introduced to glass dishes containing CCL21-agarose spots and the number of cells entering the agarose spot was visualized by acquisition of microscope images. (b) DCs ( $10^5$ ) labeled with increasing PFCE concentrations of both basic and DPPE-enriched  $^{19}\text{F}$  nanoparticles were introduced to glass dishes containing CCL21-agarose spots and the number of cells entering the agarose spot was determined by acquiring and fusing the microscope images for all the fields of views (FOV) and counting all cells entering the corresponding spot. This experiment is representative of 3.

From the spectral representation of the cell dilution curves it was already evident that far less DPPE-NP labeled DCs could be detected than basic-NP labeled DCs (Figure 5A). It should be noted that in these experiments (in line with the chemotaxis assays above) we used low PFCE labeling doses ( $5 \mu\text{mol}$  per  $10^7$  cells) in contrast to previously published work where we commonly employed  $20 \mu\text{mol}$  per  $10^7$  cells<sup>5,6,12</sup>. In the present experiments we observed that a minimum of  $10^5$  DCs labeled with basic nanoparticles ( $5 \mu\text{mol}$ ) were required to achieve a detectable  $^{19}\text{F}$  signal. However for DPPE-NP labeled DCs,  $1.5 \times 10^5$  of cells could be detected (Figure 5A). Following quantification of the  $^{19}\text{F}$  signal from the FID fit and calculation of the intracellular PFCE amount (using PFCE standard), we observed that  $10^5$  DPPE-NP labeled DCs give a similar  $^{19}\text{F}$  signal and contain similar PFCE amounts ( $14.48 \text{ nmol}$ ) as  $10^6$  basic-NP labeled DCs ( $10.45 \text{ nmol}$ ). It can also be deduced from the spectral representations (Figure 5A) that a baseline intracellular value of approximately  $10 \text{ nmol}$  PFCE (Figure 5B) is the threshold above which DCs become detectable.

**Gain in sensitivity and cellular detection following labeling with DPPE  $^{19}\text{F}$  nanoparticles.** In order to reach the goal of this study (to identify the influence of PE nanoparticle enrichment on signal sensitivity *in vivo*), we next wanted to identify the  $^{19}\text{F}$  signal and detection limit within defined regions of interest. For this we selected DC numbers used in the cell dilution curves and performed combined  $^{19}\text{F}/^1\text{H}$  MRI (Figure 6A) as well as voxel-based  $^{19}\text{F}$  PRESS in order to quantify the  $^{19}\text{F}$  signal within this defined region (Figure 6B). We used the same radio frequency volume coil used for tracking DCs in mice, in order to be able to project our findings to the *in vivo* experiment. For the volume used to embed cells in agarose ( $100 \mu\text{l}$ ) within NMR tubes it was sufficient to place a ( $5 \times 5 \times 5$ )  $\text{mm}^3$  PRESS voxel that covered the entire sample (Figure 6B). The  $^{19}\text{F}/^1\text{H}$  MR imaging experiments showed that  $2.5 \times 10^6$  was the minimum amount of cells detected in the case of basic-NP labeled DCs and  $0.3 \times 10^6$  was the minimum for the DPPE-NP labeled DCs (Figure 6A). This corresponds to a cell detection limit of  $1.7 \times 10^6$  DCs per  $\text{mm}^3$  for basic-NP labeled DCs and  $2 \times 10^5$  DCs



**Figure 5 | Lower number of cells detected by  $^{19}\text{F}$  MRS following labeling with DPPE-enriched nanoparticles.** (a) Spectral representation of  $^{19}\text{F}$  signal acquired from different numbers of basic and DPPE-NP labeled DCs using  $5 \mu\text{mol}$  PFCE per  $10^7$  cells for  $^{19}\text{F}$  labeling.  $^{19}\text{F}$  spectra are represented from the FFT of the acquired FID. (b) The  $^{19}\text{F}$  signal was quantified from the intercept of the FID fit and the PFCE amount per  $10^6$  was calculated using a  $500 \text{ mM}$  PFCE standard.



**Figure 6 |**  $^{19}\text{F}/^1\text{H}$  MRI and Voxel-based  $^{19}\text{F}$  MRS of DCs *in vitro* and *in vivo*. (a) 3D rendering of images of PFCE standard ( $4 \times 25$  mM) and different number of DCs (labeled with basic or DPPE-enriched nanoparticles) suspended in agarose gel. Images for both  $^{19}\text{F}$  and  $^1\text{H}$  nuclei were acquired using the bSSFP sequence and post-processing of data using ImageJ (National Institutes of Health, USA, <http://imagej.nih.gov/ij>). (b) After acquisition of the bSSFP images, a  $(5 \times 5 \times 5)$  mm $^3$  voxel was placed over the whole region of cells in agarose and spectra were acquired using a PRESS-protocol for  $^{19}\text{F}$  MRS (see Methods). (c) DCs ( $10^7$ ) labeled with DPPE-enriched nanoparticles were intradermally injected in the left hind limb and DCs ( $10^7$ ) labeled with basic nanoparticles in the right hind limb of C57BL/6 mice. Three hours following intradermal application a  $(3 \times 3 \times 3)$  mm $^3$  voxel was placed around left and right popliteal lymph node and the  $^{19}\text{F}$  content measured within each lymph node using PRESS sequence as described above.



per mm<sup>3</sup> for DPPE-NP labeled DCs for an <sup>19</sup>F MR scan time of 16.85 minutes (NEX = 64). The voxel-based spectroscopy method was more sensitive in detecting <sup>19</sup>F signal:  $0.5 \times 10^6$  basic-NP labeled DCs and  $0.15 \times 10^6$  DPPE-NP labeled DCs could be detected with this method (Figure 6B). This corresponds to a cell detection limit of  $4 \times 10^3$  DCs per mm<sup>3</sup> for basic-NP labeled DCs and  $1.2 \times 10^3$  DCs per mm<sup>3</sup> for DPPE-NP labeled DCs for an <sup>19</sup>F MR scan time of 13 minutes (NEX = 512).

To study the signal and migration efficiency of DPPE-NP labeled DCs *in vivo*, we next applied DCs ( $10^7$ ) to the left hind limbs of C57BL/6 mice and compared their <sup>19</sup>F signal to those labeled with basic <sup>19</sup>F nanoparticles (right hind limb). Three hours following intradermal application we placed a ( $3 \times 3 \times 3$ ) mm<sup>3</sup> PRESS voxel around both left and right popliteal lymph node and measured the <sup>19</sup>F signal within each lymph node using PRESS sequence as described above. Both from the <sup>19</sup>F/<sup>1</sup>H MR imaging as well as from the voxel-based spectra illustrating the region-specific <sup>19</sup>F signal we observed that DPPE-NP labeled DCs gave a more prominent signal *in vivo* than the basic-NP labeled DCs (Figure 6C). Using the cell calibration curves described above (Figure 5B) and the FID values at  $t = 0$  for the PRESS spectra, we could translate the quantified <sup>19</sup>F signal to the number of cells within the specific lymph node regions: we calculated that after 3 hours  $2.85 \times 10^6$  DPPE-NP labeled DCs were present in the left lymph node and  $0.79 \times 10^5$  basic-NP labeled DCs in the right lymph nodes (Figure 6C).

## Discussion

Phosphatidylethanolamines (PEs) are aminophospholipids that constitute an integral part of biological membranes. However, PE analogs have also been employed as components of non-biological systems such as non-viral transfection agents<sup>21,22</sup> and as coatings of poorly soluble carbon nanotubes to promote cellular uptake<sup>23</sup>. In the cell, PEs are mainly found in the inner leaflet of the lipid bilayer<sup>27</sup> and make up over one fourth of the whole membrane<sup>28</sup>. PEs play a role in membrane fusion and in cell division<sup>29</sup>. These phospholipids are translocated to intracellular surfaces via ATP-dependent mechanisms to maintain asymmetrical distribution within the membrane leaflet<sup>30,31</sup>. Aminophospholipid asymmetry is necessary for preserving the viability of the cell<sup>18</sup>. The phospholipids PE, PC (phosphatidylcholine), PS (phosphatidylserine), PI (phosphatidylinositol) and SM (sphingomyelin) are irregularly distributed throughout the cellular membrane (23 : 43 : 12 : 9 of PC : PE : PS : PI/SM) in dendritic cells<sup>32</sup>. The variable distribution of phospholipids is necessary for endocytosis in DCs<sup>33,34</sup>.

In this study we investigated the influence of two PE analogs on the uptake of fluorine-rich nanoparticles into DCs. We made use of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) to enrich basic nanoparticles with PE. These PEs possess different phase transition temperatures (POPE: +25°C<sup>35</sup>; DPPE: +64°C<sup>36</sup>) and their assemblies have very different fluidity. One important difference between the two analogs is the presence of an unsaturated bond within one of the fatty acid hydrocarbon chains in POPE; both fatty acid chains in DPPE are made up of only saturated bonds (Figure 1A).

We found that anchoring DPPE to nanoparticle structures dramatically improved their uptake by DCs (Figures 1–3, Figures 5–6). We also observed an increase in cellular uptake when incorporating POPE into the nanoparticle structure; however the increased uptake was not as remarkable when compared to DPPE (Figure 1B). DSPE-PEG2000 was without any effect (Figures 1–2). In our study we chose PEG2000, with an intermediate molecular weight, in order to stabilize DSPE-based nanoparticles and secure their uptake by DCs. Larger PEG chains are associated with reduced phagocytosis: PEG2000 nanoparticles are taken up more efficiently by macrophages than PEG4000, PEG5000 and PEG10000 coated nanoparticles<sup>26,37</sup>.

Earlier studies reported that covering nanoparticles with higher MW PEG (e.g. PEG5000) prolongs their circulation time *in vivo*<sup>38–40</sup>, probably due to the decreased phagocytosis and thereby protection from the reticuloendothelial system<sup>26,37</sup>. In addition to cell uptake and circulation time, the length of the PEG block influences other biological aspects such as target recognition and uptake of delivery systems mediated by address molecules. While long PEG chains may cover the vectors, short PEG chains do not inhibit their enzymatic degradation<sup>41</sup>. Phospholipid-based drug delivery systems modified with PEG2000 are highly efficient and specific at drug targeting in tumor tissue, and remain longer in tumor tissue compared to other DSPE-based carriers with other PEG masses<sup>42–44</sup>. Molecular targeting and cellular uptake can be further enhanced by modification with vector molecules such as receptor-recognizing and cell-penetrating peptides<sup>45,46</sup>. In our study we did not modify the DSPE-PEG and do not observe any changes in uptake by DCs. Our finding correlates with transfection studies that showed that increasing number of methyl or methylene groups are progressively less active in transfection<sup>47</sup>. Furthermore, PEG-lipids were found to impair transfection efficacy<sup>22</sup>. In future it will be interesting to study the impact of peptide-modified DSPE-PEG nanoparticles to promote cellular uptake in DCs<sup>46,48</sup>.

The observation that DPPE is superior to POPE with regard to cellular uptake is however surprising since liposomal transfection formulations doped with PE analogs revealed that analogs with increasing acyl chain saturation were progressively less active than unsaturated analogs<sup>47</sup>. In our study we enriched nanoparticles generated from emulsification of PFCE with Pluronic with DPPE. Since PE is strictly bound to the cytosolic leaflet, the observed increased efficiency of internalization of DPPE-enriched nanoparticles by DCs could be explained by an active process translocating PE to the inner membrane surface. It has been shown that multiple unsaturation of the fatty acyl chain significantly decreases the interaction with cholesterol in both bilayers and monolayers<sup>19</sup>. The success of conveying nanocomplexes into the intracellular compartment is dependent on several factors: hydrophobic alkyl side chains, saturation of C-C bonds in hydrophobic moieties, the head group of the phospholipids utilized to make up the nanocarrier. In a study comparing the combination of a number of phospholipids to liposomal nanoparticles used for gene delivery, combinations containing DPPE and DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) were most effective with regards to cellular transfection<sup>49</sup>.

PE and PS aminophospholipids are present in cell-derived membrane vesicles: microparticles, microvesicles, exosomes<sup>50</sup>. Recently a study reported that PE is extensively found on the external surface of microparticles derived from various human cellular sources<sup>51</sup>. Although cell-derived membrane vesicles were first discovered as a product of platelets during blood coagulation<sup>52</sup> and thought to be cellular waste, it is now becoming clear that they play a crucial role in intercellular communication<sup>53,54</sup> that may include fusion with their target cells<sup>55</sup>. Therefore it is conceivable that DPPE-enriched nanoparticles would behave in a similar fashion as these cellular vesicles in order to translocate into intracellular compartments of DCs.

Two clear differences between POPE and DPPE that could explain the differences in cellular uptake are: (i) the presence of an unsaturated bond in POPE and (ii) their dissimilar phase transition temperatures from fluid to liquid crystalline of +25°C for POPE<sup>35</sup> and +64°C for DPPE<sup>36</sup>. These distinct differences between 2 otherwise very similar PEs might determine differences in the fluidity of their assemblies and rigidity of their bilayers, thereby conveying differences in the stability of the particulate structures. The character of the acyl chains in aminophospholipids such as PEs has indeed been shown to be crucial for the fluidity of a monolayer; saturated chains lead to lesser membrane fluidity than unsaturated ones<sup>56</sup>. It was recently proposed that aminophospholipids with unsaturated oleoyl chains such as POPE are more prominent in areas of protrusion due



to their overall conical shape and aminophospholipids consisting of solely saturated palmitoyl chains (that are considered less conical/more cylindrical in shape) do not participate in curvature formation<sup>57</sup>. Curvature stress is indeed antagonized by addition of more cylindrical lipids<sup>58</sup>. Changes in the fluidity of biological membranes is also attributed to changes in membrane-initiated signaling processes; for instance, alcohol potentiation of calcium-activated potassium channels is favored by cylindrical phospholipids and blunted by conical ones, regardless of phospholipid head group charge<sup>59</sup>. Differences in membrane fluidity for DPPE and POPE nanoparticles might influence their interaction with DCs and perhaps the mechanism of entry into the cells. In future, it will be interesting to study the mode of internalization for different rigid and fluidic nanostructures by performing inhibition studies of specific uptake routes (e.g. energy-dependent processes, clathrin-mediated endocytosis, caveolae-mediated endocytosis, macropinocytosis)<sup>60</sup> and to follow nanoparticle uptake over time using time-lapse video microscopy<sup>61</sup>. State-of-the-art technologies such as computational modeling<sup>62</sup> or four-dimensional electron microscopy<sup>63</sup> will shed light in the future on structure–property relationships of nanocomposites and single-nanoparticle structural dynamics.

In the present study we showed that the incorporation of DPPE in <sup>19</sup>F nanoparticles for labeling of DCs increases the intracellular <sup>19</sup>F signal in DCs by at least one order of magnitude compared to <sup>19</sup>F nanoparticles devoid of DPPE. The observation of an increased uptake of <sup>19</sup>F nanoparticles was demonstrated by <sup>19</sup>F MR spectroscopy as well as electron and laser scanning microscopy. The microscopy studies demonstrated that nanoparticles are located inside discrete cytosolic endosomes after internalization by DCs, excluding the possibility of cell surface attachment. The agarose spot chemotaxis assay showed that DCs were less capable at moving towards a chemokine concentration when increasing <sup>19</sup>F label concentration. Although the migration capability of DCs labeled with DPPE-enriched fluorine nanoparticles is diminished when compared to non-enriched nanoparticles, when given at the same PFCE labeling concentration, lower concentrations of DPPE-enriched fluorine nanoparticles still resulted in a higher <sup>19</sup>F signal per million cells and minimal decrease in migration, implying a possible threshold for aminophospholipid enriched nanoparticle labelling concentration that increases the <sup>19</sup>F MRS signal without influencing DC migration ability. The order of magnitude increase in <sup>19</sup>F signal we observed with <sup>19</sup>F spectroscopy could be translated into two advantages: (i) we could decrease the concentration of the <sup>19</sup>F label (PFCE) from 20  $\mu$ mol (employed in our original studies<sup>5,6,12</sup>) to 5  $\mu$ mol per 10<sup>7</sup> DCs and thus decrease the impact of the <sup>19</sup>F label on cell migration and (ii) the sensitivity gain considerably improved the cell detection limit to enable imaging and quantification of DCs within specific anatomical regions *in vivo*.

In conclusion, we present evidence that an enrichment of <sup>19</sup>F nanoparticles with DPPE aminophospholipids enhances their uptake by DCs, thereby promoting cellular detection by various <sup>19</sup>F MRI and MRS methods. By promoting cellular uptake of <sup>19</sup>F label in cellular transplants — such as in DC vaccines for cancer therapy — we contribute to some of the solutions required to overcome the limitations and challenges of cellular MR imaging, particularly with respect to the barriers pertaining to detection limit and signal sensitivity.

## Methods

**Nanoparticle preparation.** Nanoparticles with high fluorine content were prepared by emulsifying Perfluoro-15-crown-5-ether (PFCE, Fluorochem, Derbyshire, UK) via direct sonication, using a ultrasonic homogenizer (Hielscher Ultrasonic GmbH, Teltow, Berlin, Germany). PFCE was emulsified in Pluronic F-68 (Sigma-Aldrich, Germany) for 10 minutes on ice (1.2 M end concentration) to generate a basic formulation: Basic <sup>19</sup>F nanoparticles (NP). To enrich the basic particles with DPPE (*1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine*, Figure 1A, Avanti Polar Lipid, Inc., Alabaster, AL) diluted Pluronic-basic nanoparticles were mixed with DPPE and further emulsified using the same conditions to obtain a final PFCE concentration of

400 mM and varying DPPE concentrations of 2.5–25  $\mu$ M (DPPE <sup>19</sup>F NP). The same procedure was used to prepare the Pluronic-Rhodamine-DPPE (DPPE-Rhodamine <sup>19</sup>F NP) and nanoparticles enriched with POPE (*1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine*, Figure 1A, Avanti Polar Lipid, Inc., Alabaster, AL). DSPE-PEG2000—PFCE nanoparticles were prepared by first coating a vial with 10 mg of DSPE-PEG2000 (*1,2-distearyl-sn-glycero-3-phosphoethanolamine*—*N[methoxy(polyethylene glycol) -2000]*, Avanti Polar Lipid, Inc., Alabaster, AL) and then sonicating PFCE in the vial for 10 minutes on ice, to achieve a final concentration of 120 mM PFCE and 3.75 mM DSPE-PEG2000.

**Zeta potential and other physical characteristics of nanoparticles.** To study the physical characteristics of the above nanoparticles, dynamic light scattering (DLS) data was obtained using a Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK), backscatter detection at 173 degrees and 635 nm laser module at 25°C. DLS provides information on a number of parameters including intensity-weighted z-average diameter, peak diameter and width, zeta ( $\zeta$ ) potential and polydispersity index (PDI). All these physical characteristics of the different nanoparticles were documented and are shown in Table 1. The z-average diameter was used for particle size since it gives an intensity-weighted harmonic diameter and is ideal for comparing different analyses. The PDI is extrapolated from the DLS function and quantitatively describes the particle size distribution best. PDI ranges from 0.01 for monodispersed particles to 0.7 for particles that have a very broad size distribution. The generated nanoparticles have a PDI < 0.3, indicating a relatively low polydispersity and narrow size distribution. The  $\zeta$  potential was also indirectly determined by measuring the electrophoretic mobility of the nanoparticles under a constant voltage of 40 mV at 25°C.

**Cryotransmission Electron Microscopy (Cryo-TEM) of Nanoparticles.** Nanoparticle preparations were plunge-frozen onto glow discharged holey carbon grids (Quantifoil Micro Tools, Jena, Germany) in liquid ethane using the environment-controlled Vitrobot (Vitrobot MarkIV, FEI, Eindhoven, The Netherlands). Briefly, 3  $\mu$ l of the nanoparticle solution were applied onto the grid which was held by tweezers inside the climate chamber (22°C, 100% relative humidity) of the Vitrobot. The solution was automatically blotted with filter paper leaving a thin film of the nanoparticle solution over the holes. The film was allowed to relax for 10 s prior to plunge freezing the sample on the grid in liquid ethane cooled near to its freezing point. Vitrified nanoparticle samples were imaged at -170°C using a Gatan cryo-transfer holder (Gatan 626, Gatan Inc. Pleasanton, USA) and standard low-dose imaging conditions (1 e<sup>-</sup>/Å<sup>2</sup>·s)<sup>64</sup> at a Tecnai G2 F20 transmission electron microscope (FEI, Oregon, USA), operated at 200 kV. Images were acquired at  $\times$  25,000 magnification on a 2k  $\times$  2k CCD camera (894 Ultrascan 1000, Gatan Inc., Pleasanton, USA).

**DC Preparation.** DCs were prepared from bone marrow (BM) suspensions as previously described<sup>65</sup>. Briefly, BM from femurs of C57BL/6 mice were grown in RPMI-1640 medium containing 10% FCS (Biochrom, Germany) and supplemented with 30 ng/ml GM-CSF. After 9 days in culture, DCs were incubated overnight in the presence of different <sup>19</sup>F nanoparticle preparations (end PFCE concentration ranging from 0.1–2 mM or 2–40  $\mu$ mol/10<sup>6</sup> cells depending on the experiment) and 1  $\mu$ g/ml full-length chicken EndoGrade ovalbumin (endotoxin conc. < 1 EU/mg; Hyglos, Regensburg, Germany) and 0.5  $\mu$ g/ml lipopolysaccharide (LPS). Following incubation, unbound <sup>19</sup>F nanoparticles were washed thoroughly from the culture dishes by washing with warm PBS. DCs were then harvested and prepared for the ensuing experiments.

**Transmission Electron Microscopy (TEM) of DCs.** DCs were fixed for 24 hours in PBS containing 2% glutaraldehyde and postfixed for 2 h with 1% osmium tetroxide. Cell pellets were then dehydrated in an ascending series of ethanol and embedded in Poly/Bed 812 (Polysciences, Eppelheim, Germany). Ultrathin sections were stained with uranyl acetate and lead citrate. Sections were imaged using a FEI Morgagni electron microscope (FEI, Eindhoven, The Netherlands) and iTEM software<sup>66</sup>.

**Laser Scanning Microscopy (LSM) of DCs.** Intracellular fluorescence in DCs labeled with fluorescently-labeled nanoparticles was investigated using an LSM780 laser scanning microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany). DCs were harvested on day 9, washed and seeded onto 4-chamber  $\mu$ -slide plates (Ibidi GmbH, München, Germany) and after 4 h labeled with <sup>19</sup>F nanoparticles. Prior to LSM, unbound nanoparticles were washed thoroughly from the  $\mu$ -slide plates by washing with warm culture medium.

**Chemotaxis of DCs.** DC motility towards chemokine following labeling with <sup>19</sup>F nanoparticles was determined using an agarose spot assay, as previously described<sup>66</sup>. Briefly, a 0.5% agarose solution was prepared, cooled to 40°C and mixed with chemokine (2000 ng/ml CCL21) or PBS (as -ve control); thereafter the agarose solution was pipetted as 10  $\mu$ l spots onto 35-mm glass dishes (MatTek Corporation, Ashland, MA, USA). Following harvesting, DCs labeled with <sup>19</sup>F nanoparticles were introduced, together with culture medium, to the glass dishes and incubated for 4 h at 37°C (5% CO<sub>2</sub>). The number of cells entering the agarose spot was determined by acquiring and fusing the microscope images for all the fields of views (FOV) making up the 10  $\mu$ l agarose spot and counting all cells entering the corresponding spot. Image processing (including FOV fusion) and analysis (mainly cell counting) were done with Fiji (Image JA v1.47p, Open source software, NIH, Bethesda, Maryland, USA)<sup>67</sup>. For fusing all images the *Stitching* plugin was used and for counting the



number of cells within the spot a semi-automatic procedure using the *3D Objects Counter* analyze tool was used.

**In vitro <sup>19</sup>F MR Spectroscopy (MRS).** Following harvesting, DCs (10<sup>6</sup>) labeled with <sup>19</sup>F nanoparticles were fixed in 2% PFA and transferred to NMR tubes (external diameter: 4.947 ± 0.019 mm; Wall thickness: 0.043 ± 0.02 mm; VWR International GmbH, Darmstadt, Germany) and the uptake of <sup>19</sup>F nanoparticles monitored by <sup>19</sup>F spectroscopy. For this we employed an in-house built <sup>19</sup>F-tuned loop RF coil<sup>5</sup> for signal transmission and reception on a 9.4 T animal MRI scanner (Biospec 94/20 USR, Bruker Biospin, Ettlingen, Germany). A 90° block pulse with 10 kHz bandwidth was used for <sup>19</sup>F signal excitation. Spectral representation was done by performing a fast Fourier transformation (FFT) of the acquired free induction decay (FID). The amount of PFCE in each sample was calculated from the amplitude of the extrapolated monoexponential decay, at t = 0 of the FID, which is proportional to the <sup>19</sup>F concentration. A standard consisting of 500 mM PFCE was used as quantitative reference in all of these experiments. To determine the cell detection limit of <sup>19</sup>F labeling, voxel-based <sup>19</sup>F spectroscopy was performed in phantom experiments using increasing numbers of <sup>19</sup>F-labeled DCs. Fixed cells were suspended in 2% agarose and transferred to NMR tubes. An NMR tube holder made of acrylonitrile butadiene styrene (ABS) material was printed in-house using a 3D rapid prototyping system (BST 1200es, Dimension Inc., Eden Prairie, MN, USA) and customized to fit within a <sup>1</sup>H/ <sup>19</sup>F dual-tunable volume RF coil (35 mm inner diameter, 50 mm length; Rapid Biomed, Würzburg, Germany). For quantification of the <sup>19</sup>F content within the fixed cells in the NMR tubes, we employed Point REsolved SpectroScopy (PRESS) single voxel spectroscopy. For this purpose we placed a (5 × 5 × 5) mm<sup>3</sup> voxel within the region of interest covering the whole cells in agarose (Figure 6). Then we employed the FastMap<sup>68</sup> method for volume specific magnetic field (B<sub>0</sub>) shimming. After B<sub>0</sub> shimming, the spectra were acquired using a PRESS-protocol for <sup>19</sup>F MRS: TR = 1500 ms, TE = 11.6 ms, voxel size (5 × 5 × 5) mm<sup>3</sup>, number of repetitions = 512, scan time = 13 min.

**In vitro <sup>19</sup>F and <sup>1</sup>H MRI of Dendritic Cells.** To image the fluorine content within the NMR tubes holding the fixed cells labeled with <sup>19</sup>F nanoparticle we performed 3D balanced steady state free precession (bSSFP) MRI on the 9.4 T animal MRI using a custom made <sup>1</sup>H/ <sup>19</sup>F dual-tunable volume birdcage resonator (Rapid Biomed, Würzburg, Germany) with 35 mm inner diameter and 50 mm length. The bSSFP sequence was chosen because it was also used for the in vivo experiments (described below); it has been shown previously to provide very high SNR, allowing for high spatiotemporal resolution image acquisitions in reasonable scan times, and because it produces very good soft tissue contrast, related to their T<sub>2</sub>/T<sub>1</sub> relaxation times<sup>69</sup>. The scan parameters for bSSFP were as follows for proton (<sup>1</sup>H) scans: TR = 6.7 ms, TE = 3.3 ms, flip angle = 30°, matrix = 256 × 128 × 128, field of view (FOV) = (5.8 × 2.9 × 5.8) cm<sup>3</sup>, (227 × 227 × 453) μm<sup>3</sup> spatial resolution, number of excitations (NEX) = 1, scan time = 63 sec. For fluorine (<sup>19</sup>F) scans the parameters for bSSFP were: TR = 3.6 ms, TE = 1.8 ms, flip angle = 30°, matrix = 64 × 32 × 32, FOV = (5.8 × 2.9 × 5.8) cm<sup>3</sup>, (906 × 906 × 1813) μm<sup>3</sup> spatial resolution, NEX = 64, scan time = 16.85 min. To reduce banding artefacts across the SSFP images for both nuclei, 4 acquisitions were made using a 0°, 90°, 180° and 270° phase cycling scheme. The four acquisitions were combined by the sum of squares method using ImageJ (National Institutes of Health, USA, <http://imagej.nih.gov/ij>).

**In vivo <sup>19</sup>F <sup>1</sup>H MRI and <sup>19</sup>F MRS.** Animal experiments were carried out in accordance with the guidelines provided and approved by the Animal Welfare Department of the LAGESo State Office of Health and Social Affairs Berlin (Permit G0070/09: *Migration v. Immunzelltherapien*). Following harvesting, <sup>19</sup>F-labeled DCs were thoroughly washed in serum-free buffer and administered intradermally (5 × 10<sup>6</sup>) into the hind limb of C57BL/6 mice and imaged between 4–18 h following injection. Shortly before and during the MR session, mice were anesthetized using a mixture of isoflurane as inhalation narcosis (0.5–1.5%), pressurized air and oxygen. Mice were imaged on the 9.4 T animal MRI using the same <sup>1</sup>H/ <sup>19</sup>F dual-tunable volume birdcage resonator as above (Rapid Biomed, Würzburg, Germany) and the same 3D bSSFP pulse sequences. The temperature of the mice was regulated at 37°C. The respiration rate and temperature was monitored by remote monitoring system (Model 1025, SA Instruments Inc., NY, USA). For quantification of the <sup>19</sup>F content within the lymph node regions, we employed the PRESS sequence as above after placing a (3 × 3 × 3) mm<sup>3</sup> voxel around the lymph nodes. After FastMap for volume selective B<sub>0</sub> shimming, <sup>19</sup>F spectra within the lymph nodes were acquired using the same PRESS-protocol for <sup>19</sup>F MRS as above.

**MR Data Collection and Analysis.** For both in vivo and in vitro MR-measurements a Redhat RHEL4 system and Paravision v5 (Bruker Biospin, Ettlingen, Germany) software were used. NMR data processing, analysis and spectral presentation were performed in the Matlab environment (Matlab version 7.10.0.499, R2010a, The MathWorks, Inc., Natick, Massachusetts, USA). Differences between groups were analyzed by the student t-test. A p-value of p < 0.05 was considered to be statistically significant.

1. Dekaban, G. A. *et al.* Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. *Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology* **5**, 469–483, doi:10.1002/wnn.1227 (2013).

2. Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. *Immunity* **39**, 38–48, doi:10.1016/j.jimmuni.2013.07.004 (2013).
3. Ahrens, E. T., Flores, R., Xu, H. & Morel, P. A. In vivo imaging platform for tracking immunotherapeutic cells. *Nat.Biotechnol.* **23**, 983–987 (2005).
4. Srinivas, M., Heerschap, A., Ahrens, E. T., Figgdr, C. G. & de Vries, I. J. <sup>19</sup>F MRI for quantitative in vivo cell tracking. *Trends Biotechnol.* **28**, 363–370 (2010).
5. Waiczies, H. *et al.* Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. *PLoS One* **6**, e21981 (2011).
6. Waiczies, H. *et al.* Monitoring Dendritic Cell Migration using <sup>19</sup>F/1H Magnetic Resonance Imaging. *J Vis Exp.* doi: 10.3791/50251 (2013).
7. de Vries, I. J. *et al.* Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. *Nat.Biotechnol.* **23**, 1407–1413 (2005).
8. Brooks, R. A., Brunetti, A., Alger, J. R. & Di Chiro, G. On the origin of paramagnetic inhomogeneity effects in blood. *Magn Reson.Med.* **12**, 241–248 (1989).
9. Lee, N., Inouye, M. & Lauterbur, P. C. <sup>19</sup>F- and <sup>13</sup>C-NMR studies of a specifically labelled lipoprotein in the *Escherichia coli* membrane. *Biochemical and biophysical research communications* **78**, 1211–1218 (1977).
10. Holland, G. N., Bottomley, P. A. & Hinshaw, W. S. <sup>19</sup>F-19 Magnetic-Resonance Imaging. *Journal of Magnetic Resonance* **28**, 133–136 (1977).
11. Liu, M. S. & Long, D. M. Perfluorocetyltribromide as a diagnostic contrast medium in gastroenterography. *Radiology* **122**, 71–76 (1977).
12. Waiczies, H. *et al.* Visualizing brain inflammation with a shingled-leg radio-frequency head probe for <sup>19</sup>F/1H MRI. *Sci.Rep.* **3**, 1280 (2013).
13. Bégué, J.-P. & Bonnet-Delpont, D. *Bioorganic and medicinal chemistry of fluorine*. (John Wiley & Sons, 2008).
14. Gerechtzoff, G., Li-Blatter, X., Fischer, H., Frentzel, A. & Seelig, A. Halogenation of drugs enhances membrane binding and permeation. *Chembiochem : a European journal of chemical biology* **5**, 676–684, doi:10.1002/cbic.200400017 (2004).
15. Smart, B. E. Fluorine substituent effects (on bioactivity). *J Fluorine Chem* **109**, 3–11, doi:Doi 10.1016/S0022-1139(01)00375-X (2001).
16. Banchereau, J. & Palucka, A. K. Dendritic cells as therapeutic vaccines against cancer. *Nature Reviews Immunology* **5**, 296–306 (2005).
17. Ahrens, E. T., Helfer, B. M., O'Hanlon, C. F. & Schirda, C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. *Magnetic Resonance in Medicine*, doi:doi: 10.1002/mrm.25454 (2014).
18. Balasubramanian, K. & Schroit, A. J. Aminophospholipid asymmetry: A matter of life and death. *Annu Rev Physiol* **65**, 701–734, doi:DOI 10.1146/annurev.physiol.65.092101.142459 (2003).
19. Smaby, J. M., Brockman, H. L. & Brown, R. E. Cholesterols Interfacial Interactions with Sphingomyelins and Phosphatidylcholines - Hydrocarbon Chain Structure Determines the Magnitude of Condensation. *Biochemistry-US* **33**, 9135–9142, doi:Doi 10.1021/Bi00170a016 (1994).
20. Sprong, H., van der Sluijs, P. & van Meer, G. How proteins move lipids and lipids move proteins. *Nat Rev Mol Cell Biol* **2**, 504–513 (2001).
21. Felgner, J. H. *et al.* Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. *Journal of Biological Chemistry* **269**, 2550–2561 (1994).
22. Hyvönen, Z. *et al.* Doleoyl phosphatidylethanolamine and PEG-lipid conjugates modify DNA delivery mediated by 1, 4-dihydropyridine amphiphiles. *Journal of Controlled Release* **99**, 177–190 (2004).
23. Antonelli, A. *et al.* Improved cellular uptake of functionalized single-walled carbon nanotubes. *Nanotechnology* **21**, 425101 (2010).
24. Caliceti, P. & Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. *Advanced drug delivery reviews* **55**, 1261–1277 (2003).
25. Allen, T. M., Hansen, C., Martin, F., Redemann, C. & Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. *Biochimica et biophysica acta* **1066**, 29–36 (1991).
26. Fang, C. *et al.* In vivo tumor targeting of tumor necrosis factor- $\alpha$ -loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. *European Journal of Pharmaceutical Sciences* **27**, 27–36, doi:<http://dx.doi.org/10.1016/j.ejps.2005.08.002> (2006).
27. Zachowski, A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. *The Biochemical journal* **294** ( Pt 1), 1–14 (1993).
28. Virtanen, J. A., Cheng, K. H. & Somerharju, P. Phospholipid composition of the mammalian red cell membrane can be rationalized by a superlattice model. *Proceedings of the National Academy of Sciences of the United States of America* **95**, 4964–4969 (1998).
29. Emoto, K. *et al.* Redistribution of phosphatidylethanolamine at the cleavage furrow of dividing cells during cytokinesis. *Proceedings of the National Academy of Sciences* **93**, 12867–12872 (1996).
30. Riekhof, W. R. & Voelker, D. R. Uptake and utilization of lyso-phosphatidylethanolamine by *Saccharomyces cerevisiae*. *Journal of Biological Chemistry* **281**, 36588–36596 (2006).
31. Muller, K., Pomorski, T., Muller, P., Zachowski, A. & Herrmann, A. Protein-dependent translocation of aminophospholipids and asymmetric transbilayer distribution of phospholipids in the plasma membrane of ram sperm cells. *Biochemistry-US* **33**, 9968–9974 (1994).



32. Laulagnier, K. *et al.* Mast cell-and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. *Biochem. J.* **380**, 161–171 (2004).

33. Steinman, R. M., Mellman, I. S., Muller, W. A. & Cohn, Z. A. Endocytosis and the recycling of plasma membrane. *The Journal of cell biology* **96**, 1–27 (1983).

34. Steinman, R. M., Brodie, S. E. & Cohn, Z. A. Membrane flow during pinocytosis. A stereologic analysis. *The Journal of cell biology* **68**, 665–687 (1976).

35. Wang, X. & Quinn, P. J. Cubic phase is induced by cholesterol in the dispersion of 1-palmitoyl-2-oleoyl-phosphatidylethanolamine. *Biochimica et Biophysica Acta (BBA)-Biomembranes* **1564**, 66–72 (2002).

36. Arouri, A., Dathe, M. & Blume, A. Peptide induced demixing in PG/PE lipid mixtures: a mechanism for the specificity of antimicrobial peptides towards bacterial membranes? *Biochimica et Biophysica Acta (BBA)-Biomembranes* **1788**, 650–659 (2009).

37. Fontana, G., Licciardi, M., Mansueto, S., Schillaci, D. & Giammona, G. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake. *Biomaterials* **22**, 2857–2865, doi:[http://dx.doi.org/10.1016/S0142-9612\(01\)00030-8](http://dx.doi.org/10.1016/S0142-9612(01)00030-8) (2001).

38. Klibanov, A. L., Maruyama, K., Torchilin, V. P. & Huang, L. Amphiphatic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett* **268**, 235–237 (1990).

39. Klibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P. & Huang, L. Activity of amphiphatic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1062**, 142–148, doi:[http://dx.doi.org/10.1016/0005-2736\(91\)90385-L](http://dx.doi.org/10.1016/0005-2736(91)90385-L) (1991).

40. Mori, A., Klibanov, A. L., Torchilin, V. P. & Huang, L. Influence of the steric barrier activity of amphiphatic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. *FEBS Lett* **284**, 263–266, doi:[http://dx.doi.org/10.1016/0014-5793\(91\)80699-4](http://dx.doi.org/10.1016/0014-5793(91)80699-4) (1991).

41. Koren, E., Apte, A., Sawant, R. R., Grunwald, J. & Torchilin, V. P. Cell-penetrating TAT peptide in drug delivery systems: Proteolytic stability requirements. *Drug delivery* **18**, 377–384, doi:[10.3109/10717544.2011.567310](http://dx.doi.org/10.3109/10717544.2011.567310) (2011).

42. Lukyanov, A., Gao, Z., Mazzola, L. & Torchilin, V. Polyethylene Glycol-Diacyllipid Micelles Demonstrate Increased Accumulation in Subcutaneous Tumors in Mice. *Pharm Res* **19**, 1424–1429, doi:[10.1023/a:1020488012264](http://dx.doi.org/10.1023/a:1020488012264) (2002).

43. Torchilin, V. P. Micellar Nanocarriers: Pharmaceutical Perspectives. *Pharm Res* **24**, 1–16, doi:[10.1007/s11095-006-9132-0](http://dx.doi.org/10.1007/s11095-006-9132-0) (2007).

44. Kale, A. A. & Torchilin, V. P. "Smart" Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes. *Journal of Liposome Research* **17**, 197–203, doi:[10.1080/08982100701525035](http://dx.doi.org/10.1080/08982100701525035) (2007).

45. Sydow, K., Torchilin, V. P. & Dathe, M. Lipopeptide-modified PEG-PE-based pharmaceutical nanocarriers for enhanced uptake in blood–brain barrier cells and improved cytotoxicity against glioma cells. *European Journal of Lipid Science and Technology* **116**, 1174–1183, doi:[10.1002/ejlt.201300373](http://dx.doi.org/10.1002/ejlt.201300373) (2014).

46. Sauer, I., Dunay, I. R., Weisgraber, K., Bienert, M. & Dathe, M. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. *Biochemistry-Us* **44**, 2021–2029 (2005).

47. Felgner, J. H. *et al.* Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. *Journal of Biological Chemistry* **269**, 2550–2561 (1994).

48. Sydow, K., Torchilin, V. P. & Dathe, M. Lipopeptide-modified PEG-PE-based pharmaceutical nanocarriers for enhanced uptake in blood–brain barrier cells and improved cytotoxicity against glioma cells. *European Journal of Lipid Science and Technology* **116**, 1174–1183, doi:[10.1002/ejlt.201300373](http://dx.doi.org/10.1002/ejlt.201300373) (2014).

49. Ramezani, M., Khoshhamdam, M., Dehshahri, A. & Malaekeh-Nikouei, B. The influence of size, lipid composition and bilayer fluidity of cationic liposomes on the transfection efficiency of nanolipoplexes. *Colloid Surface B* **72**, 1–5, doi:[10.1016/j.colsurfb.2009.03.018](http://dx.doi.org/10.1016/j.colsurfb.2009.03.018) (2009).

50. van Dommelen, S. M. *et al.* Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. *Journal of Controlled Release* **161**, 635–644, doi:[10.1016/j.conrel.2011.11.021](http://dx.doi.org/10.1016/j.conrel.2011.11.021) (2012).

51. Larson, M. C., Woodliff, J. E., Hillery, C. A., Kearn, T. J. & Zhao, M. Phosphatidylethanolamine is externalized at the surface of microparticles. *Biochimica et biophysica acta* **1821**, 1501–1507, doi:[10.1016/j.bbapli.2012.08.017](http://dx.doi.org/10.1016/j.bbapli.2012.08.017) (2012).

52. Wolf, P. The nature and significance of platelet products in human plasma. *British journal of haematology* **13**, 269–288 (1967).

53. Roseblade, A. *et al.* Cell-derived microparticles: new targets in the therapeutic management of disease. *Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques* **16**, 238–253 (2013).

54. Hargett, L. A. & Bauer, N. N. On the origin of microparticles: From "platelet dust" to mediators of intercellular communication. *Pulmonary circulation* **3**, 329–340, doi:[10.4103/2045-8932.114760](http://dx.doi.org/10.4103/2045-8932.114760) (2013).

55. Deregibus, M. C. *et al.* Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. *Blood* **110**, 2440–2448, doi:[10.1182/blood-2007-03-078709](http://dx.doi.org/10.1182/blood-2007-03-078709) (2007).

56. Saulnier, P., Foussard, F., Boury, F. & Proust, J. Structural properties of asymmetric mixed-chain phosphatidylethanolamine films. *Journal of colloid and interface science* **218**, 40–46 (1999).

57. Malcharek, S., Hinz, A., Hilterhaus, L. & Galla, H.-J. Multilayer structures in lipid monolayer films containing surfactant protein C: effects of cholesterol and POPE. *Biophysical Journal* **88**, 2638–2649 (2005).

58. Epanet, R. M. & Bottega, R. Determination of the phase behaviour of phosphatidylethanolamine admixed with other lipids and the effects of calcium chloride: implications for protein kinase C regulation. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **944**, 144–154, doi:[http://dx.doi.org/10.1016/0005-2736\(89\)90427-0](http://dx.doi.org/10.1016/0005-2736(89)90427-0) (1988).

59. Crowley, J. J., Treistman, S. N. & Dopico, A. M. Distinct Structural Features of Phospholipids Differentially Determine Ethanol Sensitivity and Basal Function of BK Channels. *Mol Pharmacol* **68**, 4–10, doi:[10.1124/mol.105.012971](http://dx.doi.org/10.1124/mol.105.012971) (2005).

60. Gratton, S. E. A. *et al.* The effect of particle design on cellular internalization pathways. *Proceedings of the National Academy of Sciences* **105**, 11613–11618, doi:[10.1073/pnas.0801763105](http://dx.doi.org/10.1073/pnas.0801763105) (2008).

61. Champion, J. A. & Mitragotri, S. Role of target geometry in phagocytosis. *Proceedings of the National Academy of Sciences of the United States of America* **103**, 4930–4934, doi:[10.1073/pnas.0600997103](http://dx.doi.org/10.1073/pnas.0600997103) (2006).

62. Yan, L.-T. & Xie, X.-M. Computational modeling and simulation of nanoparticle self-assembly in polymeric systems: Structures, properties and external field effects. *Progress in Polymer Science* **38**, 369–405 (2013).

63. van der Veen, R. M., Kwon, O.-H., Tissot, A., Hauser, A. & Zewail, A. H. Single-nanoparticle phase transitions visualized by four-dimensional electron microscopy. *Nature chemistry* **5**, 395–402 (2013).

64. Adrian, M., Dubochet, J., Lepault, J. & McDowall, A. W. Cryo-electron microscopy of viruses. *Nature* **308**, 32–36 (1984).

65. Bendix, I. *et al.* MAPK3 deficiency drives autoimmunity via DC arming. *European journal of immunology* **40**, 1486–1495, doi:[10.1002/eji.200939930](http://dx.doi.org/10.1002/eji.200939930) (2010).

66. Wiggins, H. & Rapoport, J. An agarose spot assay for chemotactic invasion. *BioTechniques* **48**, 121–124, doi:[10.2144/000113353](http://dx.doi.org/10.2144/000113353) (2010).

67. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**, 676–682, doi:[10.1038/Nmeth.2019](http://dx.doi.org/10.1038/Nmeth.2019) (2012).

68. Gruetter, R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. *Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine* **29**, 804–811 (1993).

69. Economopoulos, V., Noad, J. C., Krishnamoorthy, S., Rutt, B. K. & Foster, P. J. Comparing the MRI appearance of the lymph nodes and spleen in wild-type and immuno-deficient mouse strains. *PLoS One* **6**, e27508, doi:[10.1371/journal.pone.0027508](http://dx.doi.org/10.1371/journal.pone.0027508) (2011).

## Acknowledgments

This study was funded by the *Deutsche Forschungsgemeinschaft* to SW (DFG WA 2804). We thank Ms. Stefanie Kox and Ms. Yvonne Balke for excellent technical support.

## Author contributions

S.W., S.L. and T.N. contributed to the manuscript text; S.W., S.L., K.S., S.D., M.C.K., C.M., D.L., I.S. and B.F. performed the experiments; S.W., S.L., H.R.M., H.W., M.D. and A.P. analyzed the data. All authors reviewed the manuscript.

## Additional information

**Competing financial interests:** S.W. received research grants and poster honoraria from Novartis. K.S. was partly financed by the DFG (DA 324/9-1). H.W. is employed by and T.N. is founder of MRI.TOOLS GmbH. T.N. received speaker honoraria from Siemens Healthcare, Erlangen, Germany. M.D. now works with Siemens Healthcare. S.L., S.D., M.C.K., C.M., D.L., I.S., H.R.M., B.F., M.D. and A.P. have nothing to disclose.

**How to cite this article:** Waiczies, S. *et al.* Anchoring Dipalmitoyl Phosphoethanolamine to Nanoparticles Boosts Cellular Uptake and Fluorine-19 Magnetic Resonance Signal. *Sci. Rep.* **5**, 8427; DOI:[10.1038/srep08427](http://dx.doi.org/10.1038/srep08427) (2015).

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>